Portola Pharmaceuticals (PTLA) Receiving Somewhat Favorable News Coverage, Accern Reports

Media coverage about Portola Pharmaceuticals (NASDAQ:PTLA) has been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Portola Pharmaceuticals earned a news impact score of 0.07 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 47.4226118763243 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Portola Pharmaceuticals (NASDAQ PTLA) traded up $1.29 on Tuesday, hitting $50.80. The stock had a trading volume of 601,928 shares, compared to its average volume of 982,420. Portola Pharmaceuticals has a 1-year low of $17.15 and a 1-year high of $67.10. The company has a quick ratio of 8.31, a current ratio of 8.31 and a debt-to-equity ratio of 0.24.

Portola Pharmaceuticals (NASDAQ:PTLA) last released its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($1.41) EPS for the quarter, topping the consensus estimate of ($1.49) by $0.08. Portola Pharmaceuticals had a negative return on equity of 110.46% and a negative net margin of 938.19%. The business had revenue of $3.83 million during the quarter, compared to analyst estimates of $4.71 million. During the same period last year, the business posted ($1.64) earnings per share. The company’s quarterly revenue was down 58.9% on a year-over-year basis. equities research analysts predict that Portola Pharmaceuticals will post -4.95 earnings per share for the current fiscal year.

PTLA has been the subject of several recent analyst reports. Morgan Stanley reissued an “overweight” rating and set a $81.00 target price (up previously from $75.00) on shares of Portola Pharmaceuticals in a research note on Friday, October 6th. Credit Suisse Group raised Portola Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $70.00 target price for the company in a research note on Wednesday, August 23rd. Oppenheimer Holdings, Inc. set a $80.00 target price on Portola Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, October 6th. BidaskClub raised Portola Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, July 24th. Finally, Zacks Investment Research cut Portola Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, August 8th. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $65.15.

TRADEMARK VIOLATION WARNING: This piece was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.chaffeybreeze.com/2017/11/21/portola-pharmaceuticals-ptla-receiving-somewhat-favorable-news-coverage-accern-reports.html.

Portola Pharmaceuticals Company Profile

Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

Insider Buying and Selling by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply